Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
CRM
IHD
KymriahⓇ - CD19 CAR-T
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03570892 BELINDA (CCTL019H2301)
2nd line Diffuse large B-cell lymphoma (DLBCL)
Phase 3
318
Event-free Survival (EFS)
Tisagenlecleucel versus standard of care
Adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of
rituximab and anthracycline- containing frontline immunochemotherapy
Target Patients
Read-out Milesstone(s)
9 Jul 2021 (actual)
Publication
Bishop et al at SITC 2019
Abstract submission TBD
NCT03876769 CASSIOPEIA (CCTL019G2201J)
1st line high risk acute lymphoblastic leukemia (ALL)
Phase 2
160
Disease Free Survival (DFS)
Single-arm study of tisagenlecleucel
Pediatric and young adult patients with 1st line high risk ALL
2025
TBD
122 Investor Relations | Q3 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation